TARS - Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc Logo

TARS - Tarsus Pharmaceuticals Inc

https://www.tarsusrx.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.

52W High
$59.76
52W Low
$29.92
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.82
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.23
EV/Revenue (<3 favorable)
7.19
P/S (TTM) (<3 favorable)
8.23
P/B (<3 favorable)
7.31
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
3.24%
Institutions (25–75% balanced)
118.14%
Shares Outstanding
42,214,100
Float
30,351,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
295,521,000
Gross Profit (TTM)
216,901,000
EPS (TTM)
-2.29
Profit Margin (>10% good)
-0.31%
Operating Margin (TTM) (higher better)
-0.22%
ROE (TTM) (>15% strong)
-0.32%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
1.52
Momentum
Bearish momentum
Value
3.8217
Previous
4.0615
Trend
Falling
Signal Cross
No cross
As of
Sep. 05, 2025